Side-by-side · Research reference
EpitalonvsSermorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft8/37 cited
BPhase 3Reviewed14/43 cited
Epitalon
Pineal bioregulator · Telomerase activator
SQ or IM · Abdomen · Daily for 10–20 days
Sermorelin
GHRH 1-29 fragment · Short-acting
SQ · Pre-sleep · 1×/day
01Mechanism of Action
Parameter
Epitalon
Sermorelin
Primary target
Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003
Pituitary GHRH receptorWalker 1994
Pathway
Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994
Downstream effect
Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003
Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013
Feedback intact?
—
Yes — short pulse preserves feedback
Origin
Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003
Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994
Antibody development
—
—
02Dosage Protocols
Parameter
Epitalon
Sermorelin
Standard dose
5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003
Anecdotal community protocol. Russian clinical literature uses similar cycling.
100–500 mcg per injectionMolteno 2013
Frequency
Once daily during a cycle
Once daily, pre-sleep
Lower / starter dose
2.5 mg / day
100 mcg per dose
Evidence basis
In-vitro telomerase + Russian clinical trialsKhavinson 2003
Phase 3 (Geref pediatric); clinical practiceWalker 1994Molteno 2013
Duration
10–20 day cycles, 1–2× per year
8–12 weeks per cycle
Reconstitution
Bacteriostatic water
Bacteriostatic water
Timing
Pre-sleep preferred (pineal alignment)
Pre-sleep, fasted preferred
Half-life
Hours (estimated)
~12 min (plasma)Molteno 2013
Shorter than tesamorelin (~26 min) — simpler GHRH analogue.
04Side Effects & Safety
Parameter
Epitalon
Sermorelin
Injection site reaction
Mild irritation
Mild erythema, transient pain
Sleep architecture
Improved subjective sleep quality (anecdotal)
—
Cancer risk
Theoretical via telomerase activation in pre-malignant cells
Contraindicated in active malignancy (GH/IGF-1 axis)
Long-term safety
Limited Western RCT data
—
Pregnancy / OB
Avoid
Avoid
Antibody formation
Not reported
—
Flushing / headache
—
Common transient effect
IGF-1 elevation
—
Modest at standard doses
Glucose handling
—
Generally neutral
Absolute Contraindications
Epitalon
- ·Pregnancy / breastfeeding
- ·Active malignancy or pre-malignant state
Sermorelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
Epitalon
- ·Family history of cancer
Sermorelin
- ·Untreated diabetes
05Administration Protocol
Parameter
Epitalon
Sermorelin
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Injection site
SQ — abdomen preferred. Rotate sites.
SQ — abdomen or thigh. Rotate sites.
3. Timing
Pre-sleep preferred to align with pineal axis.
Pre-sleep, fasted.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G, 4–8 mm insulin syringe.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Epitalon
— no documented stacks
Sermorelin
+ Ipamorelin
StrongSermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.
- Sermorelin
- 200–300 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition